Focus: Sagent Pharmaceuticals is a specialty injectable small molecule pharma company headquartered in Illinois, focused on bacterial infections and neurology with a peak-lifecycle antibiotic franchise.
Profile data last refreshed 3h ago · AI intelligence enriched 2w ago
Stable — net -3 jobs in 30d
0 added, 3 removed. Backfill posture.
Best suited for commercial professionals seeking stable revenue from established products; high risk for R&D and long-term career growth due to weak pipeline and patent cliff exposure.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Flagship product generating 56% of company revenue; NDA original formulation at peak lifecycle stage with no disclosed LOE date.
Help build intelligence for Sagent Pharmaceuticals
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Sagent Pharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Second-largest revenue product post-LOE; ANDA generic indicating mature market with competitive pressure.
ANDA daptomycin formulation post-LOE; reflects generic competition in same therapeutic space as flagship.
23 discontinued, 61 duplicate formulations not shown
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
+64 more products
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo